Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus
400 mg BID) in patients with NSCLC with KRAS G12C mutation.